In its continued bid to waylay the launch of MSN Pharmaceuticals’ proposed Entresto generic, Novartis has told a federal ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

Novartis admitted the email broke several rules set out in the U.K. marketing code. In a long response to the PMCPA, the ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

Detailed data will be presented at a future medical meeting and submitted for regulatory review later this year.

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Regulus filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, which includes, among other things, the recommendation of Regulus’s board of directors that Regulus’s stockholders ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Companies face increasingly complex decisions over what IP to use, particularly when collaborating. Muireann Bolger hears the ...

Seven pharmaceutical giants with a presence in New Jersey have announced billions in expansions. The timing is no surprise, health care analysts say.

Novartis AG blocked MSN Laboratories Pvt. Ltd.’s attempt to launch a copy of its blockbuster Entresto before July 16, as a ...